<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Cystic hygroma (CH) is characterized by abnormal accumulation of fluid in the region of the fetal neck and is a major anomaly associated with aneuploidy. Morphologically characterized by failure of the lymphatic system to communicate with the venous system in the neck, the clinical manifestations of CH depend on its size and location. Incidence is estimated at one case per 6000-16,000 live births. CH has autosomal dominant or autosomal recessive inheritance. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, couple risk assessment and access to clinical trials.</p></abstract>

Cystic hygroma (CH) is characterized by abnormal accumulation of fluid in the region of the fetal neck and is a major anomaly associated with aneuploidy. Morphologically characterized by failure of the lymphatic system to communicate with the venous system in the neck, the clinical manifestations of CH depend on its size and location. Incidence is estimated at one case per 6000-16,000 live births. CH has autosomal dominant or autosomal recessive inheritance. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, couple risk assessment and access to clinical trials.

<div xmlns="http://www.w3.org/1999/xhtml"><sec id="j_ebtj-2018-0029_s_001_w2aab3b7b6b1b6b1ab1aAa"><div>Cystic hygroma</div><p>(Other synonyms: Cystic hygroma of the neck)</p></sec><sec id="j_ebtj-2018-0029_s_002_w2aab3b7b6b1b6b1ab1b1Aa"><div>General information about the disease</div><p>Cystic hygroma (CH) or hygroma colli is characterized by abnormal accumulation of fluid in the region of the fetal neck and is one of the major anomalies associated with aneuploidy (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_001_w2aab3b7b6b1b6b1ab1c11b1Aa">1</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_002_w2aab3b7b6b1b6b1ab1c11b2Aa">2</a>). In contrast with simple increased nuchal translucency, CH is considered a possible cause of perinatal disability (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_003_w2aab3b7b6b1b6b1ab1c11b3Aa">3</a>).</p><p>CH presents as a single or multiloculated fluid-filled cavity, usually in the neck. Morphologically characterized by failure of the lymphatic system to communicate with the venous system in the neck, it often leads to hydrops and fetal death (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_004_w2aab3b7b6b1b6b1ab1c11b4Aa">4</a>).</p><p>Clinical manifestation depends on cyst size and location. CH usually causes functional impairment of nearby structures and organs, as well as disfigurement of affected areas (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_005_w2aab3b7b6b1b6b1ab1c11b5Aa">5</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_006_w2aab3b7b6b1b6b1ab1c11b6Aa">6</a>). When identified postnatally, it usually appears as a soft bulge under the skin (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_007_w2aab3b7b6b1b6b1ab1c11b7Aa">7</a>). The size of the cavities may increase due to infection or bleeding within the cyst. The cyst may exert pressure on other structures, causing swallowing difficulties, obstructive sleep apnea, airway obstruction, hemorrhage, infection and deformation of surrounding bony structures and teeth (if left untreated) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_008_w2aab3b7b6b1b6b1ab1c11b8Aa">8</a>).</p><p>Prenatal diagnosis of CH via ultrasound is based on demonstration of a bilateral, largely symmetrical, septate or non septate cystic structure in the occipitocervical region (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_009_w2aab3b7b6b1b6b1ab1c11b9Aa">9</a>).</p><p>Ultrasonographic diagnosis of septate CH is relatively easy, and chromosome analysis by chorion villus sampling or amniocentesis is generally accepted as a sequential step in its management (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_003_w2aab3b7b6b1b6b1ab1c11b3Aa">3</a>).</p><p>The incidence of CH is estimated at one case per 6000-16,000 live births (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_010_w2aab3b7b6b1b6b1ab1c11c10Aa">10</a>). CH can be part of a chromosome disorder or a monogenic syndrome or can manifest as an isolated trait (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_011_w2aab3b7b6b1b6b1ab1c11c11Aa">11</a>). Mendelian CH has autosomal dominant (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_012_w2aab3b7b6b1b6b1ab1c11c12Aa">12</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_013_w2aab3b7b6b1b6b1ab1c11c13Aa">13</a>) or autosomal recessive inheritance (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_014_w2aab3b7b6b1b6b1ab1c11c14Aa">14</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_015_w2aab3b7b6b1b6b1ab1c11c15Aa">15</a>).</p><p>Differential diagnosis should consider Meige disease, yellow nail syndrome and capillary, arteriovenous malformations, especially RASopathies.</p><sec id="j_ebtj-2018-0029_s_002_s_001_w2aab3b7b6b1b6b1ab1b1b8Aa"><div>Autosomal dominant syndromic CH</div><list list-type="bullet"><list-item><p>Achondrogenesis type II (ACG2, OMIM disease 200610) - <italic>COL2A1</italic> (OMIM gene 120140) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_016_w2aab3b7b6b1b6b1ab1c11c16Aa">16</a>)</p></list-item><list-item><p>Cornelia de Lange syndrome-1 (CDLS1, OMIM disease 122470) – <italic>NIPBL</italic> (OMIM gene 608667) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_017_w2aab3b7b6b1b6b1ab1c11c17Aa">17</a>)</p></list-item><list-item><p>Lymphedema-distichiasis syndrome (OMIM disease 153400) - <italic>FOXC2</italic> (OMIM gene 602402) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_013_w2aab3b7b6b1b6b1ab1c11c13Aa">13</a>);</p></list-item><list-item><p>Noonan syndrome-1 (NS1, OMIM disease 163950) - <italic>PTPN11</italic> (OMIM gene 176876) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_018_w2aab3b7b6b1b6b1ab1c11c18Aa">18</a>);</p></list-item><list-item><p>Noonan syndrome-3 (NS3, OMIM disease 609942) - <italic>KRAS</italic> (OMIM gene 190070) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_018_w2aab3b7b6b1b6b1ab1c11c18Aa">18</a>);</p></list-item><list-item><p>Noonan syndrome-5 (NS5, OMIM disease 611553) - <italic>RAF1</italic> (OMIM gene 164760) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_018_w2aab3b7b6b1b6b1ab1c11c18Aa">18</a>).</p></list-item></list></sec><sec id="j_ebtj-2018-0029_s_002_s_002_w2aab3b7b6b1b6b1ab1b1b9Aa"><div>Autosomal recessive syndromic CH</div><list list-type="bullet"><list-item><p>Carpenter syndrome-1 (CRPT1, OMIM disease 201000) - <italic>RAB23</italic> (OMIM gene 606144) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_019_w2aab3b7b6b1b6b1ab1c11c19Aa">19</a>)</p></list-item><list-item><p>Congenital erythropoietic porphyria (CEP, OMIM disease 263700) – <italic>UROS</italic> (OMIM gene 606938) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_020_w2aab3b7b6b1b6b1ab1c11c20Aa">20</a>)</p></list-item><list-item><p>Multiple pterygium syndrome, lethal type (LMPS, OMIM disease 253290) - <italic>CHRNA1</italic> (OMIM gene 100690), <italic>CHRND</italic> (OMIM gene 100720), <italic>CHRNG</italic> (OMIM gene 100730) and <italic>NEB</italic> (OMIM gene 161650) (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_021_w2aab3b7b6b1b6b1ab1c11c21Aa">21</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_022_w2aab3b7b6b1b6b1ab1c11c22Aa">22</a>)</p></list-item></list><p>Since a link may exist between CH and genes involved in angiogenesis and lymphangiogenesis, these genes can be also evaluated (<a ref-type="bibr" href="#j_ebtj-2018-0029_ref_013_w2aab3b7b6b1b6b1ab1c11c13Aa">13</a>, <a ref-type="bibr" href="#j_ebtj-2018-0029_ref_023_w2aab3b7b6b1b6b1ab1c11c23Aa">23</a>).</p></sec><sec id="j_ebtj-2018-0029_s_002_s_003_w2aab3b7b6b1b6b1ab1b1c10Aa"><div>Other likely genes</div><p><italic>ADAMTS3 (OMIM gene 605011), AKT1 (OMIM gene 164730), BRAF (OMIM gene 164757), CBL (OMIM gene 165360), CCBE1 (OMIM gene 612753), CELSR1 (OMIM gene 604523), EPHB4 (OMIM gene 600011), FAT4 (OMIM gene 612411), FLT4 (OMIM gene 136352), GATA2 (OMIM gene 137295), GJA1 (OMIM gene 121014), GJC2 (OMIM gene 608803), HGF (OMIM gene 142409), HRAS (OMIM gene 190020), IKBKG (OMIM gene 300248), ITGA9 (OMIM gene 603963), KIF11 (OMIM gene 148760), MAP2K1 (OMIM gene 176872), MAP2K2 (OMIM gene 601263), NRAS (OMIM gene 164790), PIEZO1 (OMIM gene 611184), PIK3CA (OMIM gene 171834), PTPN14 (OMIM gene 603155), RASA1 (OMIM gene 139150), RIT1 (OMIM gene 609591), SHOC2 (OMIM gene 602775), SOS1 (OMIM gene 182530), VEGFC (OMIM gene 601528)</italic>.</p><p>Pathogenic variants may include missense, nonsense, splicing, small insertions, small deletions, small indels, gross insertions, duplications and complex rearrangements.</p></sec></sec><sec id="j_ebtj-2018-0029_s_003_w2aab3b7b6b1b6b1ab1b2Aa"><div>Aims of the test</div><list list-type="bullet"><list-item><p>To determine the gene defect responsible for the disease;</p></list-item><list-item><p>To confirm clinical diagnosis;</p></list-item><list-item><p>To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.</p></list-item></list></sec><sec id="j_ebtj-2018-0029_s_004_w2aab3b7b6b1b6b1ab1b3Aa"><div>Test characteristics</div><sec id="j_ebtj-2018-0029_s_004_s_001_w2aab3b7b6b1b6b1ab1b3b1Aa"><div>Expert centers/ Published Guidelines</div><p>The test is listed in the GTR database, offered by 1 accredited medical genetic laboratories in the US.</p><p>Guidelines for clinical use of the test are described in Genetics Home Reference (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ghr.nlm.nih.gov">ghr.nlm.nih.gov)</ext-link></p></sec><sec id="j_ebtj-2018-0029_s_004_s_002_w2aab3b7b6b1b6b1ab1b3b2Aa"><div>Test strategy</div><p>A multi-gene next generation sequencing panel is used for the detection of nucleotide variations in coding exons and flanking introns of the above genes.</p><p>Potentially causative variants and regions with low coverage are Sanger-sequenced. Sanger sequencing is also used for family segregation studies.</p><p>Multiplex Ligation Probe Amplification (MLPA) may be used for detection of duplications and deletions in <italic>COL2A1, NIPBL, FOXC2, KRAS, UROS</italic></p><p>To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K<sub>3</sub>EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.</p><p>Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of “unknown or uncertain significance” may acquire clinical importance.</p></sec></sec><sec id="j_ebtj-2018-0029_s_005_w2aab3b7b6b1b6b1ab1b4Aa"><div>Genetic test results</div><sec id="j_ebtj-2018-0029_s_005_s_001_w2aab3b7b6b1b6b1ab1b4b1Aa"><div>Positive</div><p>Identification of pathogenic variants in the above genes confirms the clinical diagnosis and is an indication for family studies.</p><p>A pathogenic variant is known to be causative for a given genetic disorder based on previous reports, or predicted to be causative based on loss of protein function or expected significant damage to proteins or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.</p></sec><sec id="j_ebtj-2018-0029_s_005_s_002_w2aab3b7b6b1b6b1ab1b4b2Aa"><div>Inconclusive</div><p>Detection of a variant of unknown or uncertain significance (<italic>VUS</italic>): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is <italic>likely benign</italic> or <italic>likely pathogenic</italic> for a given genetic disorder. In these cases, it is advisable to extend testing to the patient’s relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.</p></sec><sec id="j_ebtj-2018-0029_s_005_s_003_w2aab3b7b6b1b6b1ab1b4b3Aa"><div>Negative</div><p>The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:</p><list list-type="bullet"><list-item><p>alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments;</p></list-item><list-item><p>sequence variations in gene regions not investigated by this test, such as regulatory regions (5’ and 3’ UTR) and deep intronic regions;</p></list-item><list-item><p>variations in other genes not investigated by the present test.</p></list-item></list></sec><sec id="j_ebtj-2018-0029_s_005_s_004_w2aab3b7b6b1b6b1ab1b4b4Aa"><div>Unexpected</div><p>Unexpected results may emerge from the test, for example information regarding consanguinity, absence of family correlation or other genetically-based diseases.</p></sec></sec><sec id="j_ebtj-2018-0029_s_006_w2aab3b7b6b1b6b1ab1b5Aa"><div>Risk for progeny</div><p>If the identified pathogenic variant has autosomal dominant transmission, the probability that an affected carrier transmit the disease variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived.</p><p>In autosomal recessive mutations, both parents are usually healthy carriers. In this case, the probability of transmitting the disorder to the offspring is 25% in any pregnancy of the couple, irrespective of the sex of the child. An affected individual generates healthy carrier sons and daughters in all cases, except in pregnancies with a healthy carrier partner. In these cases, the risk of an affected son or daughter is 50%.</p></sec><sec id="j_ebtj-2018-0029_s_007_w2aab3b7b6b1b6b1ab1b6Aa"><div>Limits of the test</div><p>The test is limited by current scientific knowledge regarding the genes and diseases.</p></sec><sec id="j_ebtj-2018-0029_s_008_w2aab3b7b6b1b6b1ab1b7Aa"><div>Analytical sensitivity (proportion of positive tests when the genotype is truly present) and specificity (proportion of negative tests when the genotype is not present)</div><p>NGS Analytical sensitivity >99.99%, with a minimum coverage of 10X; Analytical specificity 99.99%.</p><p>SANGER Analytical sensitivity >99.99%; Analytical specificity 99.99%.</p><p>MLPA Analytical sensitivity >99.99%; Analytical specificity 99.99%.</p></sec><sec id="j_ebtj-2018-0029_s_009_w2aab3b7b6b1b6b1ab1b8Aa"><div>Clinical sensitivity (proportion of positive tests if the disease is present) and clinical specificity (proportion of negative tests if the disease is not present)</div><p>Clinical sensitivity: data not available.</p><p>Clinical specificity: data not available.</p></sec><sec id="j_ebtj-2018-0029_s_010_w2aab3b7b6b1b6b1ab1b9Aa"><div>Prescription appropriateness</div><p>The genetic test is appropriate when:</p><list list-type="custom"><list-item><label>a)</label><p>the patient meets the diagnostic criteria for CH;</p></list-item><list-item><label>b)</label><p>the sensitivity of the test is greater than or equal to that of tests described in the literature.</p></list-item></list></sec><sec id="j_ebtj-2018-0029_s_011_w2aab3b7b6b1b6b1ab1c10Aa"><div>Clinical utility</div><table-wrap id="j_ebtj-2018-0029_tab_001_w2aab3b7b6b1b6b1ab1c10b1Aa" position="float" orientation="portrait"><table rules="all"><thead><tr><th align="left">Clinical management</th><th align="center">Utility</th></tr></thead><tbody><tr><td align="left">Confirmation of clinical diagnosis</td><td align="center">Yes</td></tr><tr><td align="left">Differential diagnosis</td><td align="center">Yes</td></tr><tr><td align="left">Couple risk assessment</td><td align="center">Yes</td></tr><tr><td align="left" colspan="2">Availability of clinical trials can be checked on-line at <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://htps://clinicaltrials.gov/">htps://clinicaltrials.gov/</ext-link></td></tr></tbody></table></table-wrap></sec></div>

Genetic testing for cystic hygroma

Division of Medical Genetics, IRCCS Casa Sollievo della Sofferenza

The EuroBiotech Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Genetic testing for cystic hygroma"}

Cystic hygroma (CH) is characterized by abnormal accumulation of fluid in the region of the fetal neck and is a major anomaly associated with aneuploidy....

Genetic testing for cystic hygroma

Article Category: Technical Report

Online veröffentlicht: 19. Sept. 2018

Seitenbereich: 22 - 25

DOI: https://doi.org/10.2478/ebtj-2018-0029

Schlüsselwörter
Cystic hygroma, EBTNA UTILITY GENE TEST

© 2018 Paolo Enrico Maltese, Yeltay Rakhmanov, Alessandra Zulian, Angelantonio Notarangelo, Matteo Bertelli, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Genetic testing for cystic hygroma

Article Category: Technical Report

Online veröffentlicht: 19. Sept. 2018

Seitenbereich: 22 - 25

DOI: https://doi.org/10.2478/ebtj-2018-0029

SchlüsselwörterCystic hygroma, EBTNA UTILITY GENE TEST

© 2018 Paolo Enrico Maltese, Yeltay Rakhmanov, Alessandra Zulian, Angelantonio Notarangelo, Matteo Bertelli, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Schlüsselwörter
Cystic hygroma, EBTNA UTILITY GENE TEST